Midatech Pharma Plc Kurs / Umsatz
Was ist das Kurs / Umsatz von Midatech Pharma Plc?
Kurs / Umsatz von Midatech Pharma Plc ist 2.51
Was ist die Definition von Kurs / Umsatz?
Das Kurs-Umsatz-Verhältnis ist der Aktienkurs eines Unternehmens im Vergleich zu seinen Einnahmen.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Kurs / Umsatz von Unternehmen in Health Care Sektor auf LSE im Vergleich zu Midatech Pharma Plc
Was macht Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Unternehmen mit kurs / umsatz ähnlich Midatech Pharma Plc
- Kingston hat Kurs / Umsatz von 2.51
- Cadila Healthcare hat Kurs / Umsatz von 2.51
- Aberdeen Emerging Markets Investment Co hat Kurs / Umsatz von 2.51
- Pantheon International Plc hat Kurs / Umsatz von 2.51
- BHP hat Kurs / Umsatz von 2.51
- Finjan hat Kurs / Umsatz von 2.51
- Midatech Pharma Plc hat Kurs / Umsatz von 2.51
- Bachem AG hat Kurs / Umsatz von 2.51
- Exasol AG hat Kurs / Umsatz von 2.51
- Tikkurila Oyj hat Kurs / Umsatz von 2.51
- Mirum Pharmaceuticals Inc hat Kurs / Umsatz von 2.51
- Mayur Uniquoters hat Kurs / Umsatz von 2.51
- 123869 hat Kurs / Umsatz von 2.51